Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1644 1645 1651
This examiner grants 64% of resolved cases
Maureen Varina Driscoll is an examiner in Art Unit 1642 of Tech Center 1600. With 91 resolved cases, the examiner has an allowance rate of 63.7%. This rate indicates a good probability of success for patent applicants. The median days to allowance is 1271, providing a timeline for successful prosecution.
The interview lift is 40.8%, suggesting that interviews are an effective tool for securing an allowance compared to the 63.7% baseline. Practitioners should strongly consider an interview to take advantage of the 40.8% lift. The 91 resolved cases offer a baseline for these metrics.
In Tech Center 1600, the 63.7% allowance rate and 1271-day median timeline offer a strategic path for applicants in Art Unit 1642. Utilizing the 40.8% interview lift can significantly improve outcomes. These data points are essential for informed decision-making.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18283196 | MATERIALS AND METHODS FOR TREATING CANCER | Final Rejection | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 17209160 | MATERIALS AND METHODS FOR TREATING CANCER | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18038185 | HER2 TARGETING AGENT | Non-Final OA | TOHOKU UNIVERSITY |
| 18551553 | Pharmaceutical Combinations for Treating Cancer | Final Rejection | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 18533539 | METHODS AND COMPOSITIONS COMPRISING A BRAF INHIBITOR AND A PD-1 BINDING ANTAGONIST | Non-Final OA | Hoffmann-La Roche Inc. |
| 18681284 | NUCLEIC ACID STRUCTURE UTILIZING SNARE | Non-Final OA | Kao Corporation |
| 18886988 | TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 17794268 | ARTICLES OF MANUFACTURE COMPRISING ANTI PD-L1 ANTIBODIES AND THEIR USE IN THERAPY | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 18565628 | THERAPEUTIC USE OF COMBINATION INCLUDING TRIPLE AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS | Non-Final OA | HANMI PHARM. CO., LTD. |
| 17909358 | GUIDANCE AND NAVIGATION CONTROL (GNC) ANTIBODY-LIKE PROTEINSAND METHODS OF MAKING AND USING THEREOF | Non-Final OA | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. |
| 17773240 | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF | Non-Final OA | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. |
| 18000425 | SSTR-2 Binding Chimeric Antigen Receptors | Non-Final OA | University of Bari Aldo Moro |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy